RhumbLine Advisers
QNCX icon

RhumbLine Advisers’s Quince Therapeutics QNCX Stock Holding History

RhumbLine Advisers’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2
Closed -$295 – 4306
2024
Q2 		$295 Hold
2
– – ﹤0.01% 4308
2024
Q1 		$417 Hold
2
– – ﹤0.01% 4196
2023
Q4 		$413 Hold
2
– – ﹤0.01% 4208
2023
Q3 		$441 Hold
2
– – ﹤0.01% 4237
2023
Q2 		$592 Buy
+2
New +$623 ﹤0.01% 4314
2022
Q2 		– Sell
-97
Closed -$120K – 3208
2022
Q1 		$120K Buy
97
+1
+1% +$1.36K ﹤0.01% 2855
2021
Q4 		$242K Sell
96
-3
-3% -$18.3K ﹤0.01% 2776
2021
Q3 		$1.81M Buy
99
+4
+4% +$63.6K ﹤0.01% 1964
2021
Q2 		$1M Buy
95
+4
+4% +$33.5K ﹤0.01% 2245
2021
Q1 		$658K Sell
91
-6
-6% -$43.2K ﹤0.01% 2365
2020
Q4 		$538K Buy
97
+6
+7% +$53.2K ﹤0.01% 2413
2020
Q3 		$912K Sell
91
-12
-12% -$109K ﹤0.01% 2032
2020
Q2 		$956K Buy
103
+35
+51% +$321K ﹤0.01% 2067
2020
Q1 		$622K Buy
68
+13
+24% +$128K ﹤0.01% 2076
2019
Q4 		$622K Buy
+55
New +$332K ﹤0.01% 2278

Other funds holding QNCX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ECG
EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

RhumbLine Advisers's QNCX Position: Q3 2024 in Review

RhumbLine Advisers sold out of Quince Therapeutics (QNCX) in Q3 2024, closing a stake of 2 shares — an estimated $295 sold.

RhumbLine Advisers first reported a position in QNCX in Q4 2019 and held it in 15 quarters. The position peaked at $1.81M in Q3 2021. 32 funds tracked by Wall St. Rank hold QNCX as of Q3 2024.

  • RhumbLine Advisers reported no remaining Quince Therapeutics position as of Q3 2024 after selling out during the quarter.
  • RhumbLine Advisers sold 2 Quince Therapeutics shares in Q3 2024, an estimated $295.
  • RhumbLine Advisers first reported a position in Quince Therapeutics in Q4 2019 and held it in 15 quarters.
  • RhumbLine Advisers's Quince Therapeutics position peaked at $1.81M in Q3 2021.
  • 32 funds tracked by Wall St. Rank held Quince Therapeutics as of Q3 2024.

Based on RhumbLine Advisers's 13F filing for Q3 2024, filed 12 Nov 2024.